Education
About Us
Working with TipRanks
Follow Us
Optinose (OPTN)
:OPTN
OPTN Stock Chart & Stats
$9.60
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Optinose News
OPTN FAQ
What was Optinose’s price range in the past 12 months?
Currently, no data Available
What is Optinose’s market cap?
Currently, no data Available
When is Optinose’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Optinose’s earnings last quarter?
Currently, no data Available
Is Optinose overvalued?
According to Wall Street analysts Optinose’s price is currently Undervalued.
Does Optinose pay dividends?
Optinose does not currently pay dividends.
What is Optinose’s EPS estimate?
Optinose’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Optinose have?
Currently, no data Available
What happened to Optinose’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Optinose?
Currently, no hedge funds are holding shares in OPTN
Company Description
Optinose
Optinose (OPTN) is a specialty pharmaceutical company focused on developing and commercializing innovative products for patients treated by ear, nose, and throat (ENT) and allergy specialists. The company's core product, XHANCE, is a nasal spray designed to treat chronic rhinosinusitis with nasal polyps in adults. Optinose operates primarily within the healthcare and pharmaceutical sectors, leveraging its proprietary Exhalation Delivery System to provide effective treatments for ENT conditions.
Ownership Overview
―
Insiders
0.35%
Mutual Funds
― Other Institutional Investors
99.65% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---